Quick Answer
Black Diamond Therapeutics, Inc. reported Diluted EPS of $0.39 per share for fiscal year 2025.
Black Diamond Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.39 | +130.7% |
| 2024 | -$1.27 | +32.4% |
| 2023 | -$1.88 | +25.4% |
| 2022 | -$2.52 | +27.4% |
| 2021 | -$3.47 | -69.3% |
| 2020 | -$2.05 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.15 | +46.4% | +21.1% |
| June 30, 2025 | -$0.19 | +47.2% | -119.4% |
| March 31, 2025 | $0.98 | +380.0% | +450.0% |
| September 30, 2024 | -$0.28 | +37.8% | +22.2% |
| June 30, 2024 | -$0.36 | +30.8% | -2.9% |
| March 31, 2024 | -$0.35 | +38.6% | +22.2% |
| September 30, 2023 | -$0.45 | +25.0% | +13.5% |
| June 30, 2023 | -$0.52 | +17.5% | +8.8% |
- Black Diamond Therapeutics, Inc. showed an increase of +130.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Black Diamond Therapeutics, Inc.’s diluted eps has grown by 119.0% (from $2.05 per share (loss) to $0.39 per share).
- The most recent figure is from Black Diamond Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: